Efficacy and Safety of Filgotinib in Psoriatic Arthritis: A GRADE-Assessed Systematic Review and Meta-Analysis
- 1 October 2026
- journal article
- review article
- Published by SAGE Publications in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
- Vol. 19
Abstract
Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting musculoskeletal and cutaneous domains. Filgotinib, a preferential Janus kinase 1 inhibitor, has been investigated as a targeted oral therapy for PsA. Objectives: To evaluate the short-term efficacy and safety of filgotinib vs placebo in adults with PsA and assess the certainty of the evidence using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Design: The study was designed as a systematic review and meta-analysis of randomized controlled trials (RCTs). Data Sources and Methods: PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov were searched from inception to October 2025. Three RCTs involving 295 participants (173 receiving filgotinib and 122 receiving placebo) were included. Random-effects meta-analyses estimated risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes. Efficacy was assessed at weeks 12 and 16, and certainty of evidence was evaluated using GRADE. Results: At week 16, filgotinib increased American College of Rheumatology 20% response (RR, 1.91, 95% CI, 1.38 to 2.64), minimal disease activity achievement (RR, 1.73, 95% CI, 1.05 to 2.85), and Psoriatic Arthritis Response Criteria response (RR, 1.59, 95% CI, 1.27 to 1.98). Psoriasis Area and Severity Index 75% response was also higher (RR, 2.68, 95% CI, 1.78 to 4.02). Psoriatic Arthritis Disease Activity Score improved (MD, −1.03, 95% CI, −1.42 to −0.63; 277 participants). No statistically significant differences were detected in serious adverse events (RR, 1.58, 95% CI, 0.29 to 8.69) or all-cause mortality (RR, 3.05, 95% CI, 0.13 to 73.42); these estimates were imprecise. Conclusion: Filgotinib demonstrated short-term efficacy across several PsA outcomes. However, 3 short-term RCTs with limited safety events cannot establish long-term safety or comparative effectiveness. Filgotinib is not approved for PsA, and its clinical role remains unestablished. Registration: PROSPERO CRD420251235155.Keywords
This publication has 22 references indexed in Scilit:
- Recent developments for new investigational JAK inhibitors in psoriatic arthritisExpert Opinion on Investigational Drugs, 2023
- Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 StudyRheumatology and Therapy, 2022
- Filgotinib: A Clinical Pharmacology ReviewClinical Pharmacokinetics, 2022
- Psoriatic arthritisNature Reviews Disease Primers, 2021
- JAK1: Number one in the family; number one in inflammation?Rheumatology, 2021
- Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)Rheumatology, 2019
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug TherapyJAMA, 2019
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trialThe Lancet, 2018
- Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with PsoriasisDrugs, 2014
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011